NEW YORK – Hedge funds are concentrating more money in American healthcare stocks than at any point in the past five years, according to data compiled by Goldman Sachs, a positioning shift that signals growing conviction that the sector is poised to outperform as policy uncertainty partially resolves and demographic demand intensifies.
The bank’s prime brokerage division, which tracks trading activity across hundreds of funds ranging from large multi-strategy platforms to specialized healthcare vehicles, recorded net exposure to US healthcare equities reaching levels not seen since early 2021, when pandemic-driven pharmaceutical investment peaked. The data covers roughly four weeks ending July 18.
The rotation has not been quiet. Several of the sector’s largest stocks have outpaced the broader market in recent weeks, and movement in options markets suggests funds are adding exposure through instruments that benefit from continued appreciation rather than hedged positions that might indicate caution. The net long positioning has accumulated faster than most sector analysts projected at the start of the quarter.
What makes the positioning significant is what it says about a sector that spent much of the past two years in flux. Healthcare stocks lagged throughout 2024 and much of 2025 as drug-pricing reforms moved through regulatory channels, as GLP-1 obesity drugs scrambled the economics of companies treating diabetes and cardiovascular disease, and as investors rotated toward technology names with clearer secular growth stories. Medicare coverage of GLP-1 drugs like Wegovy and Zepbound has expanded considerably, reshaping insurance economics and pharmaceutical revenue projections in ways that required investors to rebuild their models from scratch.
That calculus has begun to shift. The Trump administration’s approach to pharmaceutical regulation has proven more permissive than the industry feared. FDA approval timelines have shortened under current leadership, and several high-profile drugs have cleared review faster than analysts projected. For funds that bet on biotech catalysts, the regulatory environment is more favorable than it has been in years.
“People are coming back to healthcare because the overhang of policy risk has partially lifted,” said one portfolio manager who runs a long-short fund focused on the sector, speaking on condition of anonymity because client negotiations are ongoing. “That doesn’t mean the sector is cheap. It means it’s less uncertain than it was.” The distinction matters: funds are paying elevated multiples for that reduced uncertainty, leaving limited room for earnings to disappoint.
The Goldman data also revealed notable concentration within the positioning. The bulk of new exposure is in large-cap pharmaceutical companies and managed care organizations rather than smaller biotech firms where success depends on binary clinical trial outcomes. That preference for larger, established names suggests the hedge funds driving the move are making a macro bet on sector recovery rather than company-specific catalyst plays.
Managed care companies in particular have attracted fresh attention after a difficult 2025. Rising medical costs, driven by a post-pandemic surge in elective procedures that proved more durable than expected, hit insurers’ profit margins and triggered a re-rating of the group. Several large managed care stocks fell more than twenty percent from their 2024 highs. The Goldman data suggests funds now view those declines as an entry point, a judgment that will be tested against second-quarter earnings reports due in the coming weeks from the sector’s largest players.
Large pharmaceutical companies have benefited from a different dynamic. Patent cliffs that loomed over the sector have been partially addressed through acquisitions. Pfizer, Johnson & Johnson, and AbbVie have each completed sizeable deals over the past eighteen months that filled near-term revenue gaps with new products across different therapeutic categories. Johnson & Johnson’s resolution of legacy talc litigation removes one of the sector’s most closely watched overhangs.
The GLP-1 effect continues to reshape investment logic across healthcare. Funds that positioned aggressively in Eli Lilly and Novo Nordisk through 2024 and into 2025 generated exceptional returns as the weight-loss drug market expanded beyond initial projections. The question now is whether growth can sustain at current valuation multiples or whether incremental competition will compress margins. Semaglutide safety concerns that emerged in early data have not derailed the category but have raised scrutiny on next-generation entrants that must clear a higher bar than their predecessors faced.
Medical device companies have also seen increased positioning. An aging global population and rising procedure volumes have kept revenue growth for established device makers steady and predictable, a quality that appeals to managers running multi-strategy funds that need to manage volatility across a large book. The group does not carry the headline-generating narrative of obesity drugs or immuno-oncology, but it offers more consistent earnings and lower binary event risk than many of the sector’s more celebrated corners.
Not everyone in the market shares the bullish view. Strategists at several rival banks have cautioned that healthcare valuations have already moved to reflect an optimistic scenario, leaving limited room for the expected earnings recovery to drive meaningful multiple expansion from current levels. The argument is familiar in sector rotation debates: by the time a trade becomes consensus, much of the return has been captured.
The broader macroeconomic context also matters. Federal Reserve policy remains the variable that could disrupt the trade. If Wednesday’s Fed meeting signals a more aggressive posture on rates, rate-sensitive portions of the healthcare complex could face renewed pressure. High-yield savings rates near their highest levels in more than a decade continue to pull retail capital away from equities, complicating the recovery thesis for any sector dependent on broad market participation rather than institutional positioning alone. Goldman’s data shows where the institutional money has moved. Whether that move proves prescient is a question that earnings season will begin to answer in the weeks ahead.
